What Is Immunotherapy?

Immunotherapy, also called biological therapy, is a class of medical treatment that works by modifying the activity of a patient's immune system rather than by attacking a disease agent directly. In oncology it aims to make tumor cells visible to immune effectors that would otherwise ignore them. In allergy and autoimmunity it works in the opposite direction, retraining or dampening a response that has become inappropriate. The unifying idea is that the immune system is a controllable effector, and that the therapeutic target is the control loop rather than the pathogen or tumor cell itself.

The concept is old. William Coley injected bacterial preparations into sarcoma patients in the 1890s after observing occasional tumor regression following infection, and allergen desensitization by graded injection dates to 1911. Both approaches were empirical and unreliable. What converted immunotherapy into a mainstream modality was molecular understanding of the receptors and signaling pathways that govern lymphocyte activation, which arrived through the 1980s and 1990s and made rational drug design possible.

Immune Checkpoint Blockade

T cell activation is restrained by inhibitory receptors, notably CTLA-4 and PD-1, that normally prevent runaway responses against healthy tissue. Many tumors exploit these pathways, expressing PD-L1 to switch off T cells that reach them. Checkpoint inhibitors are monoclonal antibodies that block the receptor or its ligand, removing the restraint. The National Cancer Institute's account of how checkpoint inhibitors reached the clinic traces the path from federally funded basic research beginning in the late 1970s to the first trials of these agents in patients. Ipilimumab, which blocks CTLA-4, was approved for metastatic melanoma in 2011, and the PD-1 antibody pembrolizumab has since been approved across dozens of indications. James Allison and Tasuku Honjo shared the 2018 Nobel Prize in Physiology or Medicine for the underlying discoveries. Response rates vary widely by tumor type, and immune-related adverse events, in which the released response damages colon, thyroid, liver, or lung tissue, are the principal toxicity.

Adoptive Cell Therapy

Adoptive transfer treats cells themselves as the drug. In chimeric antigen receptor T cell therapy, lymphocytes are collected from the patient by apheresis, genetically modified with a viral vector to express a synthetic receptor recognizing a tumor surface antigen such as CD19, expanded in culture, and reinfused. Reviews comparing engineered T cell therapies with checkpoint blockade note that CAR T products have produced durable remissions in refractory B cell leukemias and lymphomas while proving far harder to translate to solid tumors, where antigen heterogeneity and an immunosuppressive microenvironment limit persistence. Tumor-infiltrating lymphocyte therapy and engineered T cell receptor products follow the same logic with different targeting mechanisms. Cytokine release syndrome and neurotoxicity require intensive monitoring, and manufacturing each autologous dose is a bioprocess engineering problem in its own right.

Antibodies, Vaccines, and Desensitization

Beyond checkpoints, therapeutic monoclonal antibodies act by blocking growth factor receptors, delivering cytotoxic payloads as antibody-drug conjugates, or physically bridging T cells to tumor cells as bispecific engagers. Cytokines including interleukin-2 and interferon alfa were among the first approved immunotherapies and remain in use in limited settings. Therapeutic cancer vaccines and oncolytic viruses aim to prime a response against tumor antigens. In allergy, allergen immunotherapy administered by injection or sublingual tablet shifts the response away from IgE-mediated hypersensitivity through repeated controlled exposure. Work on the mechanism of allergen immunotherapy attributes the effect to induction of regulatory T cells and a shift toward allergen-specific IgG4, and it is widely described as the only treatment that alters the natural course of allergic disease.

Applications

Immunotherapy has applications in a range of clinical and research areas, including:

• Treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma
• Hematologic malignancies, particularly relapsed B cell leukemia and lymphoma
• Desensitization for pollen, dust mite, venom, and food allergy
• Management of autoimmune disease through targeted cytokine blockade
• Transplant tolerance induction and rejection prophylaxis
• Bioprocess and cell manufacturing engineering for autologous cell products